Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 73, Issue 4, Pages 293-300Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2012.06.012
Keywords
Aspergillus; Candida; Invasive fungal infections; Mucormycetes
Categories
Funding
- Pfizer
- Astellas
- Eisai
- Merck
- Trek
- bioMerieux
- Astellas Pharma
- Astellas Pharma US
Ask authors/readers for more resources
The Prospective Antifungal Therapy Alliance (PATH Alliance (R)) performed prospective surveillance of invasive fungal infections (IFIs) among patients hospitalized at 25 medical centers in North America between 2004 and 2008, collecting information on the epidemiology, diagnosis, treatment, and mortality rates of IFIs. In total, 7526 IFIs were identified in 6845 patients. Candida spp. (73.4%) were the most common pathogens, followed by Aspergillus spp. (13.3%), and other yeasts (6.2%). Culture was the most frequently used diagnostic test in the majority of IFI categories. Most patients with invasive candidiasis were treated with fluconazole (48.3%) and the echinocandins (34.0%), while voriconazole (45.5%) was the main antifungal agent for invasive aspergillosis. The 12-week survival rate ranged from 37.5% for hematopoietic stem cell transplant recipients to similar to 75.0% for those with HIV/AIDS. In summary, the findings of the PATH Alliance (R) registry provide a better understanding of the epidemiology of a vast variety and large numbers of IFIs. (c) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available